Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma
Metrics: PDF 478 views | HTML 762 views | ?
Piers Blombery1,2, Ella Thompson1,2, Georgina L. Ryland1, Rachel Joyce3,4, David J. Byrne1, Christine Khoo1, Stephen Lade1, Mark Hertzberg5, Greg Hapgood6, Paula Marlton6, Anand Deva7, Geoffrey Lindeman1,3,8, Stephen Fox1,2, David Westerman1,2 and Miles Prince1,2
1Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
2Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia
3Stem Cells and Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
4Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia
5Department of Haematology, Prince of Wales Hospital, University of New South Wales, Randwick, NSW, Australia
6Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia
7Surgical Infection Research Group, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia
8Department of Medicine, The University of Melbourne, Parkville, VIC, Australia
Piers Blombery, email: Piers.firstname.lastname@example.org
Keywords: lymphoma; genomics; NGS
Received: July 29, 2018 Accepted: October 25, 2018 Published: November 16, 2018
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare form of T-cell lymphoma that occurs after implantation of breast prostheses. We performed comprehensive next generation sequencing based genomic characterization of 11 cases of BIA-ALCL including sequence variant detection on 180 genes frequently mutated in haematological malignancy, genome-wide copy number assessment, structural variant detection involving the T-cell receptor loci and TRB deep-sequencing. We observed sequence variants leading to JAK/STAT activation in 10 out of 11 patients. We also observed germline TP53 mutations in two cases. In addition we detected a recurrent copy number loss involving RPL5 as well as copy number amplifications involving TNFRSF11A [RANK] (in 2 cases), MYC, P2RX7, TMEM119 and PDGFRA. In summary, our comprehensive genomic characterisation of 11 cases of BIA-ALCL has provided insight into potential pathobiological mechanisms (JAK/STAT, MYC and TP53) as well as identifying targets for future therapeutic intervention (TNFRSF11A, PDGFRA) in this rare entity.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.